{"protocolSection": {"identificationModule": {"nctId": "NCT04252287", "orgStudyIdInfo": {"id": "CR108750"}, "secondaryIdInfos": [{"id": "28431754HFA3002", "type": "OTHER", "domain": "Janssen Research & Development, LLC"}], "organization": {"fullName": "Janssen Research & Development, LLC", "class": "INDUSTRY"}, "briefTitle": "A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure", "officialTitle": "Canagliflozin: Impact on Health Status, Quality of Life, and Functional Status in Heart Failure", "acronym": "CHIEF-HF"}, "statusModule": {"statusVerifiedDate": "2022-12", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2020-03-10", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2021-11-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2021-11-09", "type": "ACTUAL"}, "studyFirstSubmitDate": "2020-01-31", "studyFirstSubmitQcDate": "2020-01-31", "studyFirstPostDateStruct": {"date": "2020-02-05", "type": "ACTUAL"}, "resultsFirstSubmitDate": "2022-11-07", "resultsFirstSubmitQcDate": "2022-12-20", "resultsFirstPostDateStruct": {"date": "2023-01-12", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-12-20", "lastUpdatePostDateStruct": {"date": "2023-01-12", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Janssen Research & Development, LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine the superiority of the effectiveness of canagliflozin 100 milligram (mg) daily versus placebo in participants with symptomatic heart failure (HF) in improving the overall Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score (TSS)."}, "conditionsModule": {"conditions": ["Heart Failure"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 476, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Canagliflozin 100 mg", "type": "EXPERIMENTAL", "description": "Participants will be administered 100 milligram (mg) immediate-release, over-encapsulated tablets (as a capsule) orally once daily for 12 weeks.", "interventionNames": ["Drug: Canagliflozin 100 mg"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants will be administered matching placebo capsules orally once daily for 12 weeks.", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "Canagliflozin 100 mg", "description": "Participants will receive 100 mg immediate-release, over-encapsulated tablets (as a capsule) orally once daily.", "armGroupLabels": ["Canagliflozin 100 mg"], "otherNames": ["JNJ-28431754", "INVOKANA"]}, {"type": "DRUG", "name": "Placebo", "description": "Participants will receive matching placebo capsules orally once daily.", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Kansas City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 12", "description": "Change from baseline in KCCQ-TSS was reported. KCCQ was a 23-item, self-administered questionnaire that measure the participant's perception of their health status, including their heart failure (HF) symptoms, impact on physical and social function and how their HF impacts the quality of life. KCCQ quantifies 7 domains: physical limitations (6 items), symptom stability (1 item), symptom frequency (4 items), symptom burden (3 items), self-efficacy (2 items), quality of life (3 items) and social limitations (4 items). Scores were generated for each domain and scaled from 0 to 100, with 0 denoting the worst and 100 the best possible status. KCCQ-TSS was average of domains- symptom frequency and symptom burden, and transformed to a single score which ranged from 0 (worst) to 100 (the best possible status), where the higher score reflected better health status.", "timeFrame": "Baseline, Week 12"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Total Daily Step Count at Week 12", "description": "Change from baseline in total daily step count at Week 12 was reported in this outcome measure. The number of steps taken per day was measured using a step activity monitor at baseline and throughout the study. Step count was measured from the Fitbit device data. The Fitbit app on the participant's phone collected all data from the Fitbit device. A negative change from baseline indicated a decrease in the number of daily steps.", "timeFrame": "Baseline, Week 12"}, {"measure": "Change From Baseline in KCCQ Individual Domain Scores (Physical Limitation and Quality of Life) at Week 12", "description": "Change from baseline in KCCQ physical limitation score and KCCQ quality of life score were reported. KCCQ was a 23-item, self-administered questionnaire that measure the participant's perception of their health status, including their heart failure (HF) symptoms, impact on physical and social function and how their HF impacts the quality of life. KCCQ quantifies 7 domains: physical limitations (6 items), symptom stability (1 item), symptom frequency (4 items), symptom burden (3 items), self-efficacy (2 items), quality of life (3 items) and social limitations (4 items). Scores were generated for each domain and scaled from 0 to 100, with 0 (worst) and 100 (the best possible status), where the higher score reflected better health status.", "timeFrame": "Baseline, Week 12"}, {"measure": "Change From Baseline in KCCQ Clinical Summary Score at Week 12", "description": "Change from baseline in KCCQ-clinical summary score was reported. KCCQ was a 23-item, self-administered questionnaire that measure the participant's perception of their health status, including their heart failure (HF) symptoms, impact on physical and social function and how their HF impacts the quality of life. KCCQ quantifies 7 domains: physical limitations (6 items), symptom stability (1 item), symptom frequency (4 items), symptom burden (3 items), self-efficacy (2 items), quality of life (3 items) and social limitations (4 items). Scores were generated for each domain and scaled from 0 to 100, with 0 denoting the worst and 100 the best possible status. KCCQ-clinical summary score was average of domains- physical limitation and total symptoms (average of symptom frequency and symptom burden), and transformed to a single score which ranged from 0 (worst) -100 (the best possible status), where the higher score reflected better health status.", "timeFrame": "Baseline, Week 12"}, {"measure": "Change From Baseline in KCCQ Overall Summary Score at Week 12", "description": "Change from baseline in KCCQ-overall summary score was reported. KCCQ was a 23-item, self-administered questionnaire that measure the participant's perception of their health status, including their heart failure (HF) symptoms, impact on physical and social function and how their HF impacts the quality of life. KCCQ quantifies 7 domains: physical limitations (6 items), symptom stability (1 item), symptom frequency (4 items), symptom burden (3 items), self-efficacy (2 items), quality of life (3 items) and social limitations (4 items). Scores were generated for each domain and scaled from 0 to 100, with 0 denoting the worst and 100 the best possible status. KCCQ- overall summary score was average of domains- physical limitation, total symptoms (average of symptom frequency and symptom burden), quality of life, and social limitation, and transformed to a single score which ranged from 0 (worst) -100 (the best possible status), where the higher score reflected better health status.", "timeFrame": "Baseline, Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n- Have clinically stable symptomatic heart failure (HF) (heart failure with reduced ejection fraction \\[HFrEF\\] and heart failure with preserved ejection fraction \\[HFpEF\\]): (A) For HFrEF: (a) ejection fraction (EF) less than or equal to (\\<=) 40 percent (%) and (b) a primary diagnosis of HF OR 2 medical visits (including virtual) with a HF diagnosis code in any position in the past 18 months (B) For HFpEF: (a) EF greater than (\\>) 40%; (b) a primary diagnosis of HF OR 2 medical visits (including virtual) with a HF diagnosis code in any position in the past 18 months, AND; (C) on a loop diuretic or spironolactone or eplerenone (mineralocorticoid receptor antagonists), in the past 18 months\n\n* Have a baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) score of less than or equal to (\\<=) 80 prior to randomization\n* Be able to read and understand English\n* Possess and have sole use (example: not shared with other users) of smartphone compatible with the Fitbit device\n* Willing/able to wear the Fitbit device on a regular basis for the 9-month study period\n\nExclusion Criteria:\n\n* Currently taking a sodium-glucose co-transporter 2 inhibitor (SGLT2i) or within the last 3 months\n* History of diabetic ketoacidosis or have type 1 diabetes mellitus (T1DM)\n* Have acute decompensated HF (exacerbation of symptomatic HF) requiring intravenous diuretics, inotropes, or vasodilators within the last 4 weeks\n* Have stage 4 or 5 Chronic Kidney Disease (that is, estimated glomerular filtration rate \\[eGFR\\] \\<30 milliliter per minute \\[ml/min\\] on dialysis) from the most recent assessment\n* Have a diagnosis of hypotension within 30 days", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Janssen Research & Development, LLC Clinical Trial", "affiliation": "Janssen Research & Development, LLC", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Mercy Clinic Cardiology - Fort Smith", "city": "Fort Smith", "state": "Arkansas", "zip": "72903", "country": "United States", "geoPoint": {"lat": 35.38592, "lon": -94.39855}}, {"facility": "University of Colorado - Anschutz Medical Campus", "city": "Aurora", "state": "Colorado", "zip": "80045", "country": "United States", "geoPoint": {"lat": 39.72943, "lon": -104.83192}}, {"facility": "Clearwater Cardiovascular Consultants", "city": "Clearwater", "state": "Florida", "zip": "33756", "country": "United States", "geoPoint": {"lat": 27.96585, "lon": -82.8001}}, {"facility": "Emory University", "city": "Atlanta", "state": "Georgia", "zip": "30022", "country": "United States", "geoPoint": {"lat": 33.749, "lon": -84.38798}}, {"facility": "St Lukes Regional Medical", "city": "Boise", "state": "Idaho", "zip": "83712", "country": "United States", "geoPoint": {"lat": 43.6135, "lon": -116.20345}}, {"facility": "OSF HealthCare Cardiovascular Institute", "city": "Peoria", "state": "Illinois", "zip": "61614", "country": "United States", "geoPoint": {"lat": 40.69365, "lon": -89.58899}}, {"facility": "Central Dupage Hospital", "city": "Winfield", "state": "Illinois", "zip": "60190", "country": "United States", "geoPoint": {"lat": 41.8617, "lon": -88.1609}}, {"facility": "Parkview Cancer Institute", "city": "Fort Wayne", "state": "Indiana", "zip": "46845", "country": "United States", "geoPoint": {"lat": 41.1306, "lon": -85.12886}}, {"facility": "University of Kansas Medical Center Research Institute", "city": "Kansas City", "state": "Kansas", "zip": "66160", "country": "United States", "geoPoint": {"lat": 39.11417, "lon": -94.62746}}, {"facility": "MedStar Health Research Institute", "city": "Hyattsville", "state": "Maryland", "zip": "20782", "country": "United States", "geoPoint": {"lat": 38.95594, "lon": -76.94553}}, {"facility": "University of Michigan", "city": "Ann Arbor", "state": "Michigan", "zip": "48109", "country": "United States", "geoPoint": {"lat": 42.27756, "lon": -83.74088}}, {"facility": "Henry Ford Hospital", "city": "Detroit", "state": "Michigan", "zip": "48202", "country": "United States", "geoPoint": {"lat": 42.33143, "lon": -83.04575}}, {"facility": "St. Luke's Hospital Kansas City", "city": "Kansas City", "state": "Missouri", "zip": "64111", "country": "United States", "geoPoint": {"lat": 39.09973, "lon": -94.57857}}, {"facility": "Mercy Health Research", "city": "Washington", "state": "Missouri", "zip": "63090", "country": "United States", "geoPoint": {"lat": 38.55811, "lon": -91.01209}}, {"facility": "Robert Wood Johnson Medical School Dept. of Medicine", "city": "Piscataway", "state": "New Jersey", "zip": "08854", "country": "United States", "geoPoint": {"lat": 40.49927, "lon": -74.39904}}, {"facility": "University Hospitals Cleveland Medical Center", "city": "Cleveland", "state": "Ohio", "zip": "44106", "country": "United States", "geoPoint": {"lat": 41.4995, "lon": -81.69541}}, {"facility": "Thomas Spann Clinic", "city": "Corpus Christi", "state": "Texas", "zip": "78412", "country": "United States", "geoPoint": {"lat": 27.80058, "lon": -97.39638}}, {"facility": "Texas Heart Institute", "city": "Houston", "state": "Texas", "zip": "30322", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}]}, "referencesModule": {"references": [{"pmid": "35228753", "type": "DERIVED", "citation": "Spertus JA, Birmingham MC, Nassif M, Damaraju CV, Abbate A, Butler J, Lanfear DE, Lingvay I, Kosiborod MN, Januzzi JL. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med. 2022 Apr;28(4):809-813. doi: 10.1038/s41591-022-01703-8. Epub 2022 Feb 28."}, {"pmid": "33724883", "type": "DERIVED", "citation": "Spertus JA, Birmingham MC, Butler J, Lingvay I, Lanfear DE, Abbate A, Kosiborod ML, Fawcett C, Burton P, Damaraju CV, Januzzi JL, Whang J. Novel Trial Design: CHIEF-HF. Circ Heart Fail. 2021 Mar;14(3):e007767. doi: 10.1161/CIRCHEARTFAILURE.120.007767. Epub 2021 Mar 16. Erratum In: Circ Heart Fail. 2021 Apr;14(4):e000068. doi: 10.1161/HHF.0000000000000068."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \\& Johnson is available at www.janssen.com/clinical-trials/transparency.\n\nAs noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu", "url": "https://www.janssen.com/clinical-trials/transparency"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "A total of 1,333 participants were screened. Of which, 476 participants were randomized in the study.", "groups": [{"id": "FG000", "title": "Placebo", "description": "Participants received placebo (matched to canagliflozin) capsule orally once daily for 12 weeks."}, {"id": "FG001", "title": "Canagliflozin 100 mg", "description": "Participants received canagliflozin 100 milligrams (mg) immediate-release, over-encapsulated tablet (as capsule) orally once daily for 12 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "238"}, {"groupId": "FG001", "numSubjects": "238"}]}, {"type": "Treated (Safety Analysis Set)", "comment": "Safety analysis set included all randomized participants who received at least 1 dose of study intervention.", "achievements": [{"groupId": "FG000", "numSubjects": "231"}, {"groupId": "FG001", "numSubjects": "224"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "207"}, {"groupId": "FG001", "numSubjects": "209"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "31"}, {"groupId": "FG001", "numSubjects": "29"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "6"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "16"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Safety analysis set included all randomized participants who received at least 1 dose of study intervention.", "groups": [{"id": "BG000", "title": "Placebo", "description": "Participants received placebo (matched to canagliflozin) capsule orally once daily for 12 weeks."}, {"id": "BG001", "title": "Canagliflozin 100 mg", "description": "Participants received canagliflozin 100 milligrams (mg) immediate-release, over-encapsulated tablet (as capsule) orally once daily for 12 weeks."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "231"}, {"groupId": "BG001", "value": "224"}, {"groupId": "BG002", "value": "455"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "63.8", "spread": "13.5"}, {"groupId": "BG001", "value": "62.9", "spread": "13.15"}, {"groupId": "BG002", "value": "63.4", "spread": "13.32"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "99"}, {"groupId": "BG001", "value": "105"}, {"groupId": "BG002", "value": "204"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "132"}, {"groupId": "BG001", "value": "119"}, {"groupId": "BG002", "value": "251"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "White", "measurements": [{"groupId": "BG000", "value": "199"}, {"groupId": "BG001", "value": "184"}, {"groupId": "BG002", "value": "383"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "35"}, {"groupId": "BG002", "value": "65"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "2"}]}, {"title": "Other", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "5"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Kansas City Cardiomyopathy Questionnaire-Total Symptom Score (KCCQ-TSS) at Week 12", "description": "Change from baseline in KCCQ-TSS was reported. KCCQ was a 23-item, self-administered questionnaire that measure the participant's perception of their health status, including their heart failure (HF) symptoms, impact on physical and social function and how their HF impacts the quality of life. KCCQ quantifies 7 domains: physical limitations (6 items), symptom stability (1 item), symptom frequency (4 items), symptom burden (3 items), self-efficacy (2 items), quality of life (3 items) and social limitations (4 items). Scores were generated for each domain and scaled from 0 to 100, with 0 denoting the worst and 100 the best possible status. KCCQ-TSS was average of domains- symptom frequency and symptom burden, and transformed to a single score which ranged from 0 (worst) to 100 (the best possible status), where the higher score reflected better health status.", "populationDescription": "Full analysis set (FAS) included all randomized participants who had received at least one dose of study intervention/medication and had at least one post-baseline KCCQ measurement. Here, N (Overall number of participants analyzed) signifies participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo (matched to canagliflozin) capsule orally once daily for 12 weeks."}, {"id": "OG001", "title": "Canagliflozin 100 mg", "description": "Participants received canagliflozin 100 milligrams (mg) immediate-release, over-encapsulated tablet (as capsule) orally once daily for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "206"}, {"groupId": "OG001", "value": "208"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.9", "spread": "1.27"}, {"groupId": "OG001", "value": "9.2", "spread": "1.27"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.016", "statisticalMethod": "ANCOVA", "paramType": "LS mean difference", "paramValue": "4.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.8", "ciUpperLimit": "7.8"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Total Daily Step Count at Week 12", "description": "Change from baseline in total daily step count at Week 12 was reported in this outcome measure. The number of steps taken per day was measured using a step activity monitor at baseline and throughout the study. Step count was measured from the Fitbit device data. The Fitbit app on the participant's phone collected all data from the Fitbit device. A negative change from baseline indicated a decrease in the number of daily steps.", "populationDescription": "FAS included all randomized participants who had received at least one dose of study intervention/medication and had at least one post-baseline KCCQ measurement. Here, N (Overall number of participants analyzed) signifies participants evaluated for this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Daily step count", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo (matched to canagliflozin) capsule orally once daily for 12 weeks."}, {"id": "OG001", "title": "Canagliflozin 100 mg", "description": "Participants received canagliflozin 100 milligrams (mg) immediate-release, over-encapsulated tablet (as capsule) orally once daily for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "208"}, {"groupId": "OG001", "value": "205"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-74.9", "spread": "112.85"}, {"groupId": "OG001", "value": "-45.1", "spread": "113.78"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.852", "statisticalMethod": "ANCOVA", "paramType": "LS mean difference", "paramValue": "29.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-284.4", "ciUpperLimit": "344.1"}]}, {"type": "SECONDARY", "title": "Change From Baseline in KCCQ Individual Domain Scores (Physical Limitation and Quality of Life) at Week 12", "description": "Change from baseline in KCCQ physical limitation score and KCCQ quality of life score were reported. KCCQ was a 23-item, self-administered questionnaire that measure the participant's perception of their health status, including their heart failure (HF) symptoms, impact on physical and social function and how their HF impacts the quality of life. KCCQ quantifies 7 domains: physical limitations (6 items), symptom stability (1 item), symptom frequency (4 items), symptom burden (3 items), self-efficacy (2 items), quality of life (3 items) and social limitations (4 items). Scores were generated for each domain and scaled from 0 to 100, with 0 (worst) and 100 (the best possible status), where the higher score reflected better health status.", "populationDescription": "FAS included all randomized participants who had received at least one dose of study intervention/medication and had at least one post-baseline KCCQ measurement. Here, N (Overall number of participants analyzed) signifies participants evaluable for this outcome measure. Here, 'n' (number analyzed) signifies participants with available data for each specified category.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo (matched to canagliflozin) capsule orally once daily for 12 weeks."}, {"id": "OG001", "title": "Canagliflozin 100 mg", "description": "Participants received canagliflozin 100 milligrams (mg) immediate-release, over-encapsulated tablet (as capsule) orally once daily for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "206"}, {"groupId": "OG001", "value": "208"}]}], "classes": [{"title": "KCCQ-Physical Limitation", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "206"}, {"groupId": "OG001", "value": "204"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.8", "spread": "1.26"}, {"groupId": "OG001", "value": "7.8", "spread": "1.27"}]}]}, {"title": "KCCQ-Quality of Life", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "206"}, {"groupId": "OG001", "value": "208"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "9.1", "spread": "1.40"}, {"groupId": "OG001", "value": "12.4", "spread": "1.41"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in KCCQ Clinical Summary Score at Week 12", "description": "Change from baseline in KCCQ-clinical summary score was reported. KCCQ was a 23-item, self-administered questionnaire that measure the participant's perception of their health status, including their heart failure (HF) symptoms, impact on physical and social function and how their HF impacts the quality of life. KCCQ quantifies 7 domains: physical limitations (6 items), symptom stability (1 item), symptom frequency (4 items), symptom burden (3 items), self-efficacy (2 items), quality of life (3 items) and social limitations (4 items). Scores were generated for each domain and scaled from 0 to 100, with 0 denoting the worst and 100 the best possible status. KCCQ-clinical summary score was average of domains- physical limitation and total symptoms (average of symptom frequency and symptom burden), and transformed to a single score which ranged from 0 (worst) -100 (the best possible status), where the higher score reflected better health status.", "populationDescription": "FAS included all randomized participants who had received at least one dose of study intervention/medication and had at least one post-baseline KCCQ measurement. Here, N (Overall number of participants analyzed) signifies participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo (matched to canagliflozin) capsule orally once daily for 12 weeks."}, {"id": "OG001", "title": "Canagliflozin 100 mg", "description": "Participants received canagliflozin 100 milligrams (mg) immediate-release, over-encapsulated tablet (as capsule) orally once daily for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "206"}, {"groupId": "OG001", "value": "208"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.7", "spread": "1.16"}, {"groupId": "OG001", "value": "8.5", "spread": "1.17"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in KCCQ Overall Summary Score at Week 12", "description": "Change from baseline in KCCQ-overall summary score was reported. KCCQ was a 23-item, self-administered questionnaire that measure the participant's perception of their health status, including their heart failure (HF) symptoms, impact on physical and social function and how their HF impacts the quality of life. KCCQ quantifies 7 domains: physical limitations (6 items), symptom stability (1 item), symptom frequency (4 items), symptom burden (3 items), self-efficacy (2 items), quality of life (3 items) and social limitations (4 items). Scores were generated for each domain and scaled from 0 to 100, with 0 denoting the worst and 100 the best possible status. KCCQ- overall summary score was average of domains- physical limitation, total symptoms (average of symptom frequency and symptom burden), quality of life, and social limitation, and transformed to a single score which ranged from 0 (worst) -100 (the best possible status), where the higher score reflected better health status.", "populationDescription": "FAS included all randomized participants who had received at least one dose of study intervention/medication and had at least one post-baseline KCCQ measurement. Here, N (Overall number of participants analyzed) signifies participants evaluable for this outcome measure.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Score on a scale", "timeFrame": "Baseline, Week 12", "groups": [{"id": "OG000", "title": "Placebo", "description": "Participants received placebo (matched to canagliflozin) capsule orally once daily for 12 weeks."}, {"id": "OG001", "title": "Canagliflozin 100 mg", "description": "Participants received canagliflozin 100 milligrams (mg) immediate-release, over-encapsulated tablet (as capsule) orally once daily for 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "206"}, {"groupId": "OG001", "value": "208"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.2", "spread": "1.18"}, {"groupId": "OG001", "value": "9.5", "spread": "1.18"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "All-cause mortality: Up to 9 months; serious adverse events and other adverse events: Up to 30 days after end of treatment (up to 4 months)", "description": "Safety analysis set included all randomized participants who received at least 1 dose of study intervention.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "Participants received placebo (matched to canagliflozin) capsule orally once daily for 12 weeks.", "deathsNumAffected": 5, "deathsNumAtRisk": 231, "seriousNumAffected": 36, "seriousNumAtRisk": 231, "otherNumAffected": 0, "otherNumAtRisk": 231}, {"id": "EG001", "title": "Canagliflozin 100 mg", "description": "Participants received canagliflozin 100 milligrams (mg) immediate-release, over-encapsulated tablet (as capsule) orally once daily for 12 weeks.", "deathsNumAffected": 3, "deathsNumAtRisk": 224, "seriousNumAffected": 33, "seriousNumAtRisk": 224, "otherNumAffected": 0, "otherNumAtRisk": 224}], "seriousEvents": [{"term": "Anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Arrhythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 224}]}, {"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Cardiac arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Cardiac failure acute", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 224}]}, {"term": "Cardiogenic shock", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Coronary artery occlusion", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Intracardiac thrombus", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Pericardial effusion", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Goitre", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Visual impairment", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Gastric ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Gastrointestinal haemorrhage", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Oesophageal stenosis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Pancreatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Oedema", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Peripheral swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 224}]}, {"term": "Sudden cardiac death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Ulcer haemorrhage", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Cholelithiasis", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "COVID-19", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 224}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Pneumonia viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 224}]}, {"term": "Urosepsis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Back injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Foot fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Hip fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Lower limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Road traffic accident", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Tendon rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Blood creatinine increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Blood glucose increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Fibrin D dimer increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Heart rate increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Oxygen saturation decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Weight increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Decreased appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Fluid overload", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Fluid retention", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Hypercalcaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Pain in extremity", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Lung neoplasm malignant", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Balance disorder", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Bell's palsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 224}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Neuropathy peripheral", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Hallucination", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Renal impairment", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Urinary retention", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Acute respiratory distress syndrome", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Choking", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Chronic obstructive pulmonary disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Epistaxis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Haemoptysis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Pleural effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Pneumonitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Pulmonary hypertension", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Cardiac operation", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Implantable defibrillator replacement", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Knee arthroplasty", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 224}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}, {"term": "Subclavian artery stenosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA Version 24.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 231}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 224}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested by the sponsor in writing, the investigator will withhold such publication for up to an additional 60 days to allow for filing of a patent application."}, "pointOfContact": {"title": "Director CVM Health Equity", "organization": "Janssen Scientific Affairs, LLC", "email": "ClinicalTrialDisclosure@its.jnj.com", "phone": "844-434-4210"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2021-02-23", "uploadDate": "2022-12-20T06:06", "filename": "Prot_002.pdf", "size": 3969439}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2021-07-19", "uploadDate": "2022-12-20T06:06", "filename": "SAP_003.pdf", "size": 5122351}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "submissionTracking": {"firstMcpInfo": {"postDateStruct": {"date": "2022-12-01", "type": "ACTUAL"}}}}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T6034", "name": "Quality of Life", "asFound": "Quality of Life", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068896", "term": "Canagliflozin"}], "ancestors": [{"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M331", "name": "Canagliflozin", "asFound": "Nasopharyngeal", "relevance": "HIGH"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}